MX2019004872A - Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer. - Google Patents

Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.

Info

Publication number
MX2019004872A
MX2019004872A MX2019004872A MX2019004872A MX2019004872A MX 2019004872 A MX2019004872 A MX 2019004872A MX 2019004872 A MX2019004872 A MX 2019004872A MX 2019004872 A MX2019004872 A MX 2019004872A MX 2019004872 A MX2019004872 A MX 2019004872A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
beta
treatment
composition
Prior art date
Application number
MX2019004872A
Other languages
English (en)
Inventor
Satlin Andrew
Fukushima Tatsuto
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019004872A publication Critical patent/MX2019004872A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

Se proporcionan métodos y terapias de combinación para tratar, prevenir y/o retardar el comienzo y/o desarrollo de enfermedad de Alzheimer usando un anticuerpo de protofibrilla anti-Aß (tal como, por ejemplo, BAN2401) y N-[3-((4aS,5R,7aS)-2-amino-5-metil-4 a,5,7,7a-tetrahidro-4H-furo[3,4-d][1,3]tiazin-7a-il)-4-fluorofeni l]-5-difluorometilpirazin-2-carboxamida y/o una sal farmacéuticamente aceptable de la misma (compuesto X).
MX2019004872A 2016-10-27 2017-10-26 Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer. MX2019004872A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413961P 2016-10-27 2016-10-27
US201662415165P 2016-10-31 2016-10-31
PCT/US2017/058587 WO2018081460A1 (en) 2016-10-27 2017-10-26 Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2019004872A true MX2019004872A (es) 2019-10-30

Family

ID=60327389

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004872A MX2019004872A (es) 2016-10-27 2017-10-26 Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.

Country Status (12)

Country Link
US (2) US20200299411A9 (es)
EP (1) EP3532485A1 (es)
JP (3) JP7116725B2 (es)
KR (2) KR102630042B1 (es)
CN (2) CN110214146B (es)
AU (2) AU2017347838B2 (es)
BR (1) BR112019008359A2 (es)
CA (1) CA3042020A1 (es)
IL (1) IL266114A (es)
MX (1) MX2019004872A (es)
SG (2) SG10201913049QA (es)
WO (1) WO2018081460A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913049QA (en) * 2016-10-27 2020-02-27 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
CN112805031A (zh) * 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
AU2022338055A1 (en) * 2021-08-30 2024-02-29 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101413615B1 (ko) 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
CA2711655C (en) * 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
BR112013016241A2 (pt) 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
EP3043774B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
EP3166970B1 (en) * 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
KR102524217B1 (ko) * 2014-10-10 2023-04-21 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 아미노디하이드로티아진 유도체의 의약 조성물
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
SG10201913049QA (en) * 2016-10-27 2020-02-27 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
KR20240015733A (ko) 2024-02-05
RU2019116018A3 (es) 2021-02-05
AU2017347838A1 (en) 2019-06-13
JP7116725B2 (ja) 2022-08-10
IL266114A (en) 2019-06-30
CA3042020A1 (en) 2018-05-03
SG11201903601QA (en) 2019-05-30
US20200299411A9 (en) 2020-09-24
CN117244056A (zh) 2023-12-19
AU2017347838B2 (en) 2023-04-27
EP3532485A1 (en) 2019-09-04
WO2018081460A1 (en) 2018-05-03
JP2022092013A (ja) 2022-06-21
BR112019008359A2 (pt) 2019-10-01
KR102630042B1 (ko) 2024-01-29
CN110214146B (zh) 2023-08-29
SG10201913049QA (en) 2020-02-27
KR20190102181A (ko) 2019-09-03
JP2023139116A (ja) 2023-10-03
JP7319421B2 (ja) 2023-08-01
US20190276560A1 (en) 2019-09-12
JP2020500165A (ja) 2020-01-09
RU2019116018A (ru) 2020-11-27
US20230146896A1 (en) 2023-05-11
CN110214146A (zh) 2019-09-06
AU2023208107A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
MX2019004872A (es) Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
WO2017176957A8 (en) Mdm2 protein degraders
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
SI3880676T1 (sl) Derivati 2,3-dihidro-1h-pirolo(3,4-c)piridin-1-ona kot zaviralci hpk1 za zdravljenje raka
PH12021550558A1 (en) Modulators of pnpla3 expression
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
PH12021550713A1 (en) Medicament for the treatment of chronic cough
EA202092540A1 (ru) Комбинации для лечения рака
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
IL289885A (en) History of n-((7,6,5,3,2,1-hexahydro-s-inden-4-yl)carbamoyl)-7,6,5,4-tetrahydrobenzofuran-2-sulfonamide and related compounds as nlpr3 modulators for the treatment of multiple sclerosis
EA201891241A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
CA3035115C (en) Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
PH12019501566A1 (en) Amide compounds and use thereof
PH12018501246A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021009717A (es) Sulfonamidas biciclicas.
WO2020102630A8 (en) Modulators of irf5 expression
WO2018211324A8 (en) Prodrugs for the treatment of disease